 |
Newsroom
|
Latest News
This section contains the latest news issued by Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of Boehringer Ingelheim Corporation. For press releases issued by other U.S. Boehringer Ingelheim subsidiaries, refer directly to those locations.
For international news, visit the Boehringer Ingelheim GmbH's Internet News Center.
The Archives contain news releases from prior years.
- June 24, 2008
New Aptivus® (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients - May 14, 2008
PRoFESS® Results Announced at XVII European Stroke Conference - May 7, 2008
Boehringer Ingelheim Committed to Advancing the Science of Hypoactive Sexual Desire Disorder - April 29 , 2008
Second Chances Study Shows Most Stroke Survivors “Very Satisfied” with their Overall Quality of Life - March 31, 2008
Landmark ONTARGET™ trial demonstrates Micardis® is equally effective as ramipril, with fewer discontinuations, in a broad high-risk cardiovascular population - February 19, 2008
Boehringer Ingelheim Pharmaceuticals, Inc. Receives
the NCQA “Seal Of Approval” - January 17, 2008
Boehringer Ingelheim announces enrollment is complete for the largest atrial fibrillation outcomes trial – The RE-LY™ Study - November 28, 2007
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune® (nevirapine) to a Ritonavir-Boosted Atazanavir–based Regimen in Treatment-Naïve HIV Patients - October 12, 2007
Boehringer Ingelheim Receives Top Honor As World’s Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey - October 10, 2007
Most Women with HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men - October 5, 2007
Aptivus® (tipranavir) Capsules Granted Full Approval by the U.S. FDA - September 17, 2007
Boehringer Ingelheim Receives 2008 Best Places to Work Corporate Equality Index Award From Human Rights Campaign - September 13, 2007
The Lancet publishes major Phase 3 Study on novel Oral Direct Thrombin Inhibitor - August 23, 2007
Think Women Talk about Everything? Think Again! - July 18, 2007
Boehringer Ingelheim Launches National Educational Initiative to Improve Awareness and Understanding of Restless Legs Syndrome (RLS) - July 11, 2007
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis - June 18, 2007
New data presented on Micardis® (telmisartan) tablets in hypertensive patients with type 2 diabetes - June 14, 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus® (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients